UNSPSC 51241552: Potassium chloride/sodium chloride/sodium hydroxide/sodium phosphate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241552 Potassium chloride/sodium chloride/sodium hydroxide/sodium phosphate is a Commodity code covering pharmaceutical active ingredients and electrolyte salts procured by state and local health systems, correctional facilities, and other public healthcare providers. State and local governments buy these chemical compounds as pharmaceutical base materials or finished pharmaceutical products—electrolyte replacements, intravenous solutions, and over-the-counter medications containing these salts. The recent activity under this code shows solicitations directed at manufacturers and pharmaceutical wholesalers who must meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements. Issuing bodies include state multistate cooperative purchasing alliances (regional consortia spanning multiple states and localities) and their member agencies—state departments, county health systems, municipal hospitals, and correctional departments. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, functions as a repeat buyer consolidating pharmaceutical procurement for participating jurisdictions.

The code shows current activity in the Upper Midwest and Pacific Northwest. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) on January 20, 2026, closing March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other consortium members. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026 for a two-year term. Evaluation weightings heavily favor price competitiveness (75 percent), with secondary weight on fixed pricing (10 percent), compliance with administrative data format and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and products must carry expiration dates of at least one year from manufacture.